RPAM
AERI

Rhenman & Partners Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Rhenman & Partners Asset Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-562,350
Closed -$4.22M – 94
2022
Q2 		$4.22M Sell
562,350
-26,850
-5% -$189K 0.48% 56
2022
Q1 		$5.36M Sell
589,200
-160,800
-21% -$1.24M 0.53% 58
2021
Q4 		$5.38M Hold
750,000
– – 0.36% 68
2021
Q3 		$8.55M Hold
750,000
– – 0.6% 52
2021
Q2 		$12M Hold
750,000
– – 0.82% 51
2021
Q1 		$13.4M Sell
750,000
-100,000
-12% -$1.73M 0.93% 44
2020
Q4 		$11.5M Hold
850,000
– – 0.94% 45
2020
Q3 		$10M Buy
850,000
+260,000
+44% +$3.17M 0.89% 44
2020
Q2 		$8.71M Sell
590,000
-130,000
-18% -$1.92M 0.94% 43
2020
Q1 		$9.72M Buy
720,000
+20,000
+3% +$379K 1.36% 32
2019
Q4 		$16.9M Buy
700,000
+225,000
+47% +$4.66M 1.85% 16
2019
Q3 		$9.13M Buy
475,000
+215,000
+83% +$4.93M 1.14% 36
2019
Q2 		$7.68M Hold
260,000
– – 0.85% 48
2019
Q1 		$12.3M Sell
260,000
-20,000
-7% -$880K 1.44% 26
2018
Q4 		$10.1M Buy
280,000
+100,000
+56% +$4.69M 1.16% 41
2018
Q3 		$11.1M Buy
180,000
+110,000
+157% +$7.07M 1.11% 43
2018
Q2 		$4.73M Buy
70,000
+30,000
+75% +$1.68M 0.48% 62
2018
Q1 		$2.17M Sell
40,000
-86,829
-68% -$4.86M 0.27% 66
2017
Q4 		$7.58M Buy
126,829
+5,897
+5% +$358K 1.02% 38
2017
Q3 		$5.88M Buy
120,932
+45,932
+61% +$2.51M 0.75% 52
2017
Q2 		$3.94M Sell
75,000
-10,000
-12% -$466K 0.57% 63
2017
Q1 		$3.85M Buy
85,000
+50,000
+143% +$2.23M 0.61% 59
2016
Q4 		$1.32M Buy
+35,000
New +$1.32M 0.25% 80

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rhenman & Partners Asset Management's AERI Position: Q3 2022 in Review

Rhenman & Partners Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 562,350 shares — an estimated $4.22M sold.

Rhenman & Partners Asset Management first reported a position in AERI in Q4 2016 and held it in 23 quarters. The position peaked at $16.9M in Q4 2019. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

  • Rhenman & Partners Asset Management reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 562,350 Aerie Pharmaceuticals shares in Q3 2022, an estimated $4.22M.
  • Rhenman & Partners Asset Management first reported a position in Aerie Pharmaceuticals in Q4 2016 and held it in 23 quarters.
  • Rhenman & Partners Asset Management's Aerie Pharmaceuticals position peaked at $16.9M in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.